In the present study, the combination of sorafenib and TMZ obviously decreased the mitochondrial membrane potential of glioma cells (Figure 3A) and increased the Bax/Bcl-2 ratio and cytosolic cytochrome c release (Figure 3B). Here, BAX is linked to glioma.